<DOC>
	<DOCNO>NCT00124813</DOCNO>
	<brief_summary>Background : In study , thalidomide combination chemotherapy show effective patient relapse refractory multiple myeloma ( MM ) . In study , researcher choose regimen administer outpatient basis . Induction therapy : To evaluate efficacy toxicity thalidomide , cyclophosphamide , oral idarubicin dexamethasone ( T-CID ) patient relapse refractory multiple myeloma . Maintenance therapy : Randomized trial compare efficacy toxicity thalidomide thalidomide plus oral idarubicin maintenance therapy patient least stable disease T-CID .</brief_summary>
	<brief_title>Thalidomide , Cyclophosphamide , Oral Idarubicin Dexamethasone ( T-CID ) Patients With Multiple Myeloma</brief_title>
	<detailed_description>Background : In study , thalidomide combination chemotherapy show effective patient relapse refractory multiple myeloma ( MM ) . In study , researcher choose regimen administer outpatient basis . After 3-8 cycle T-CID patient least stable disease randomize receive thalidomide thalidomide plus oral idarubicin maintenance therapy least one year progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients multiple myeloma accord British Columbia Cancer Agency Criteria Stage IIA/B IIIA/B accord Durie/Salmon Symptomatic progressive disease Status disease : refractory disease standard induction therapy OR relapse standard induction therapy OR relapse highdose chemotherapy/stem cell transplantation OR patient plasma cell leukemia Patients measurable paraprotein urine serum quantifiable bone marrow infiltration Written inform consent Age &lt; 18 year Life expectancy le 3 month Intolerance study drug No change progressive disease prior therapy idarubicin cyclophosphamide Cardiac insufficiency New York Heart Association ( NYHA ) grade 3 4 Acute infection Actually decompensated diabetes mellitus Total bilirubin &gt; 3.0 mg/dl Pregnant breastfeed woman Polyneuropathy grade 2 high Ulcus ventriculus duodeni Narrow open angle glaucoma Notcompensated psychiatric disease Prior erythroblastopenia Prior therapy investigational drug within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>